August 30, 2018
1 min read

Dexamethasone implant for macular edema improves VA, CRT

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Patients with macular edema who received a dexamethasone intravitreal implant experienced significantly improved best corrected visual acuity and central retinal thickness over a 1-year period, according to study.

The prospective, open-label, multicenter study included 71 patients with macular edema for less than 3 months. The primary endpoint was mean change from baseline in best corrected visual acuity (BCVA) at 6 months, and secondary was increase in BCVA of 15 letters or more at months 6 and 12.

Only 59 patients completed the 12-month study and 62 patients remained at the 6-month timepoint. Retreatment was allowed for patients at 4 months or less.

At 6 months, the mean BCVA improved by 18.6 letters; at 1 year, the mean BCVA improved by 15.3 letters. At 6 months, the mean decrease in central retinal thickness (CRT) from baseline was 246.8 m. At 1 year, the mean decrease in CRT was 196.9 m.

Across the 12-month study period, 32% of patients had one dexamethasone intravitreal implant injection, 18% had two injections, and 49% had three injections. The mean CRT of patients who received one injection was significantly thinner than in those who received three injections (P < .016). – by Robert Linnehan

Disclosures: Yoon reports receiving a research grant, consulting fees and speaker fees from Allergan plc. Please see the full study for a list of all other authors’ relevant financial disclosures.